Patient Care

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and intensifying doctors’ collaboration with dwindling...

In the Age of Automation, Human Collaboration Still Counts: Survey Highlights Critical Role of Medical Lab Staff, Influences on Doctors’ Orders

Empowered patients, inadequate healthcare coverage, and systemic pressure are factors influencing doctors’ test orders and intensifying doctors’ collaboration with dwindling...

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Mean signs and symptoms for participants in Stage 3 of the SAHARA trial remained statistically significantly better than study baseline...

error: Content is protected !!